David J. Frost

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Cherrie K. Donawho, Yan Luo, Yanping Luo et al. · Clinical Cancer Research · 2007 · 762 citations · Full text

Potent, Orally Active Heterocycle-Based Combretastatin A-4 Analogues:  Synthesis, Structure−Activity Relationship, Pharmacokinetics, and In Vivo Antitumor Activity Evaluation

Le Wang, Keith W. Woods, Qun Li et al. · Journal of Medicinal Chemistry · 2002 · 420 citations · Full text

Medicinal Chemistry, Drug Targeting, Oncology +14

A Protein Farnesyltransferase Inhibitor Ameliorates Disease in a Mouse Model of Progeria

Loren G. Fong, David J. Frost, Margarita Meta et al. · Science · 2006 · 311 citations

Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer

Thomas D. Penning, Gui‐Dong Zhu, Viraj B. Gandhi et al. · Journal of Medicinal Chemistry · 2008 · 264 citations · Full text

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

Alex R. Shoemaker, Michael J. Mitten, Jessica Adickes et al. · Clinical Cancer Research · 2008 · 209 citations